Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21003314 | 0.86 | SMN1; SMN2 (0.36) | KDM4EMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL8943390 | 0.81 | GAA (0.35) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL506259 | 0.79 | ALDH1A1 (0.40) | KDM4EMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL7333342 | 0.77 | SMN1; SMN2 (0.40) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6600592 | 0.76 | HTR4 (0.38) | KDM4EMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL5764364 | 0.75 | ABL1 (0.38) | KDM4EMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL8690082 | 0.74 | KDM4E (0.37) | KDM4EMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL7325147 | 0.73 | ALDH1A1 (0.36) | KDM4EMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL8685016 | 0.72 | PTGES (0.38) | KDM4EMAPK1ALDH1A1MEN1KMT2A | |
| SCHEMBL19888383 | 0.72 | SMN1; SMN2 (0.44) | KDM4EMAPK1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406434-B | As 5-HT4Amide compounds of receptor agonists | 苏文生命科学有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| EP-3265459-B1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2019-05-15 | — | — | EP | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-9957257-B2 | Amide compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-05-01 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-02-22 | — | — | US | disclosed |
| EP-3265459-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2018-01-10 | — | — | EP | disclosed |
| US-5610157-A | N-(3-hydroxy-4-piperidinyl) (dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzo-dioxin) carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-11 | — | — | US | disclosed |
| US-5602129-A | GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-02-11 | — | — | US | disclosed |
| US-5576448-A | GASTROINTESTINAL DISORDERS, ANTIEMETICS, ANTIPSYCHOTICS OR NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-11-19 | — | — | US | disclosed |
| US-5565582-A | GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-15 | — | — | US | disclosed |
| US-5554772-A | CHEMICAL INTERMEDIATES; GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-10 | — | — | US | disclosed |
| US-5552553-A | CHEMICAL INTERMEDIATES FOR LAXATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-03 | — | — | US | disclosed |
| US-5521314-A | CHEMICAL INTERMEDIATES FOR CENTRAL NERVOUS SYSTEM, ANTIEMETICS, ANTIPSYCHOTIC AGENTS OR NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-28 | — | — | US | disclosed |
| EP-0389037-B1 | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-09-20 | — | — | EP | disclosed |
| US-5374637-A | Stimulate gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-20 | — | — | US | disclosed |
| EP-0389037-A1 | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051011-A1 | AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | KDM4E 1149/4885MAPK1 2245/4885ALDH1A1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.